Skip to main content
Clinical Trials/NCT06741423
NCT06741423
Active, not recruiting
Not Applicable

Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases on CT Scans Via an Extended-Radiomics Approach: a Multi-Centric, International Retrospective Analysis.

Heidelberg University2 sites in 2 countries600 target enrollmentStarted: November 1, 2023Last updated:

Overview

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
600
Locations
2
Primary Endpoint
Radiomic accuracy for retroperitoneal fibrosis

Overview

Brief Summary

A retrospective study utilizing archived CT scans of patients diagnosed with retroperitoneal fibrosis, sarcoma or other malignancies (i.e. lymphoma, germ cell tumors, metastasis, infections, ganglioneuromas) in order to implement a radiomics algorithm which is able to differentiate between these malignancies.

Detailed Description

The aim of this project is to develop a radiomics algorithm that can reliably identify retroperitoneal fibrosis (Ormond's disease) and retroperitoneal sarcomas, automatically segment them and differentiate them from other retroperitoneal diseases. Radiomics is a technique that uses artificial intelligence to extract characteristics from radiological image data that are not visible to humans and to identify image morphological patterns of diseases. As it is difficult to differentiate between diseases using image data alone, clinical data such as symptoms and laboratory values are to be correlated with the image data and utilized by the algorithm. Among other things, this should increase the sensitivity, accuracy and specificity of image-based diagnostics in order to enable faster, non-invasive diagnosis.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients of any age or gender.
  • CT scans confirming the presence of a retroperitoneal mass.
  • Confirmed diagnosis of retroperitoneal fibrosis, sarcoma or other malignancies (i.e. lymphoma, germ cell tumors, metastasis, infections, ganglioneuromas) through pathology reports or clinical follow-up.

Exclusion Criteria

  • Poor quality CT scans where the region of interest is not clearly visible.
  • Previous treatments or surgeries that might alter the radiomic features of the tumors.

Outcomes

Primary Outcomes

Radiomic accuracy for retroperitoneal fibrosis

Time Frame: 6 months

Accuracy of the algorithm in differentiating between retroperitoneal fibrosis and other retroperitoneal diseases

Secondary Outcomes

  • Radiomic accuracy for retroperitoneal sarcomas(10 Months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Cui Yang

Private Lecturer Dr. med.

Heidelberg University

Study Sites (2)

Loading locations...

Similar Trials